Evidence map›Paper›PMID 33259222›Full record

ArticleMolecular pharmaceutics2021

Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension.

Emma von Witting, Sarah Lindbo, Magnus Lundqvist, Marit Möller, Andreas Wisniewski, Sara Kanje, Johan Rockberg, Hanna Tegel, Mikael Åstrand, Mathias Uhlén and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Emma von WittingProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.ORCID 0000-0002-4695-7858
Sarah LindboProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Magnus LundqvistProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Marit MöllerProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Andreas WisniewskiProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Sara KanjeProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.ORCID 0000-0002-4751-2519
Johan RockbergProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Hanna TegelProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Mikael ÅstrandProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Mathias UhlénProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Sophia HoberProtein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.ORCID 0000-0003-0605-8417

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Albumin-binding fusion partners are frequently used as a means for the

Indexed as

Bacterial ProteinsHalf-LifeLife ExpectancyProtein BindingRecombinant Fusion ProteinsSerum AlbuminStreptococcusTumor Necrosis Factor-alphaBacterial ProteinsIgG Fc-binding protein, StreptococcusRecombinant Fusion ProteinsSerum AlbuminTumor Necrosis Factor-alphaABDADAPTalbuminhalf-life extensionnext-generation sequencingphage displayprotein engineering

Identifiers

PMID33259222
PMCPMC9490751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.